AI Consensus Investment Thesis
SYK: Stryker Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Stryker: 1-Year and 5-Year Forecast Outlook and Rating
Stryker (SYK) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $316 for , with +3.81% expected return (+4.58% including net dividends) and a NEUTRAL rating.
The 5-year target is $513 for , with +68.53% expected return (+75.34% including net dividends) and a BUY rating.
Latest available market price: USD 304, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0.81%. As of 2026-10-20.
Gross TTM: 1.16% · Two-year annualized gross: 1.13%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0.7% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Stryker Flagship Insight
Operational Recovery and Outpatient Robotics Create Mispriced Surgical Cash Flows
There is high consensus that non-cyclical procedural demand and installed robotic ecosystems anchor long-term compounding, while sharp divergence persists over near-term peripheral vascular supply bottlenecks. Valuation multiple recovery remains conditional on operational recovery and hospital capital budgeting flexibility.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Michael Burry (Vulture)
Universal Investor (Polymath)
Ray Dalio (Strategist)
Warren Buffett (Value Purist)
Elon Musk (Visionary)
Superintelligence (Anthropologist)
J.P. Morgan (Titan)
Sherlock Holmes (Whistleblower)
Machiavelli (Insider)
Ran across these frontier AI models
Google Gemini 3.8 Flash
Anthropic Claude Opus 5
OpenAI GPT-6 Astra
Latest published deep-analysis batch. Audit published forecasts in full transparency
Stryker: forecast questions
What is Stryker (SYK)'s 1-year price forecast?
Stryker's 1-year target is $316 for Sept 2027. The current AI rating is NEUTRAL. The expected return from the recorded close is +3.81%, or +4.58% modeled return including net dividends. Latest available market price: USD 304, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Stryker (SYK)'s 5-year price forecast?
Stryker's 5-year target is $513 for Sept 2031. The current AI rating is BUY. The expected return from the recorded close is +68.53%, or +75.34% modeled return including net dividends. Latest available market price: USD 304, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 304, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Stryker forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Stryker differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Stryker is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Stryker: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Stryker at the latest market close (20 Oct 2026): $17,534 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
* Return is calculated incl. 0.8% net dividend yield for Stryker.
The base-case economic thesis identifies a transient valuation disconnect where market participants have priced temporary manufacturing dislocations and cyber-remediation expenses as permanent structural impairment. Underlying revenue durability is anchored by an installed base exceeding three thousand robotic systems, converting upfront capital placements into decade-long, high-margin implant consumable annuities that compound through demographic necessity. Valuation remains highly sensitive to hospital capital expenditure financing costs under five-percent sovereign yields and management's operational execution on vascular supply recovery. The primary counterargument contends that prolonged factory bottlenecks have permanently ceded thrombectomy share to competitors while hospital capex freezes cap console placements.
Key insights
- Razor-and-blade procedural mechanics generate over seventy-five percent of revenues from recurring implants, completely insulating operating cash flows from industrial cyclicality.
- Ambulatory surgical center expansion via handheld robotics unlocks high-velocity outpatient procedure volume, delivering superior operating leverage and distribution economics.
- Trailing free cash flow of $4.70 billion comfortably funds programmatic debt deleveraging, ensuring strategic resilience despite restrictive global monetary conditions.
Stryker: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 304, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0.81%. As of 2026-10-20.
Gross TTM: 1.16% · Two-year annualized gross: 1.13%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0.7% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 275. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $280 | +1.63% | -8.02% | -7.90% | Third-quarter results reflect lingering peripheral vascular backorders and hospital equipment budget caution, but resilient elective procedural volumes and initial conversion of capital backorders cushion equity downside from oversold valuation levels. | $261 | $289 | $750 | |
| $292 | +4.46% | -4.07% | -3.76% | Fourth-quarter reporting confirms manufacturing throughput stabilization across acquired vascular facilities, while full-year guidance frames realistic targets. Reduced operational downside uncertainty prompts institutional short covering and initiates measured multiple stabilization. | $280 | $306 | $736 | |
| $305 | +4.59% | +0.20% | +0.73% | Commercial scaling of handheld robotic platforms in ambulatory surgery centers unlocks outpatient procedure growth. Favorable implant pull-through and recovering vascular shipments expand adjusted operating margins, supporting solid upward earnings revisions. | $296 | $321 | $743 | |
| $316 | +3.46% | +3.81% | +4.58% | Second-quarter joint arthroplasty demand shows solid unit volume expansion across North America and Europe. High-margin consumable utilization offsets seasonal summer scheduling moderation, keeping quarterly cash generation resilient. | $304 | $334 | $755 | |
| $329 | +4.20% | +8.08% | +9.10% | Year-end hospital capital budget releases drive robotic console deliveries and digital operating suite installations. Strong operational cash flow accelerates post-acquisition balance sheet deleveraging, reinforcing investor confidence in earnings durability. | $316 | $351 | $776 | |
| $340 | +3.13% | +11.70% | +12.97% | Full-year financial reporting confirms expanding operating margins and free cash flow exceeding five billion dollars. A modest dividend increase validates capital discipline, sustaining positive momentum despite restrictive benchmark interest rates. | $319 | $372 | $787 | |
| $352 | +3.79% | +15.64% | +17.20% | Expanded clinical indications for robotic shoulder and extremity procedures broaden the commercial addressable market. High-margin reconstructive consumables drive divisional operating leverage, insulating cash flow from persistent hospital procurement scrutiny. | $328 | $387 | $803 | |
| $359 | +1.96% | +17.94% | +19.77% | Hospital financing costs and procurement reviews temporarily moderate large-scale equipment purchases during seasonal lulls. Inelastic joint and trauma consumable volumes cushion operating income, keeping quarterly price action relatively stable. | $337 | $406 | $812 | |
| $374 | +4.05% | +22.86% | +25.03% | Delayed surgical equipment orders convert ahead of fiscal year-end, while high fourth-quarter procedure throughput boosts consumable replenishment. Working capital discipline generates exceptional cash conversion, supporting steady share appreciation. | $350 | $423 | $839 | |
| $385 | +2.96% | +26.48% | +28.96% | Annual financial disclosures highlight high-single-digit organic revenue growth and sustained margin discipline. Prudent balance-sheet management reduces net debt, providing ample strategic flexibility to fund selective tuck-in acquisitions. | $359 | $444 | $851 | |
| $398 | +3.36% | +30.75% | +33.58% | European and Asian adoption of robotic-assisted joint replacement accelerates, alleviating waiting lists and expanding international revenues. Incremental software licensing and consumable revenues outpace rising regulatory compliance costs. | $370 | $461 | $872 | |
| $409 | +2.65% | +34.36% | +37.56% | Demographic tailwinds provide steady baseline volume growth across hips and knees. Moderate competitive pricing pressure from rival robotic platforms is offset by surgeon loyalty and sticky hospital workflow integration. | $377 | $475 | $886 | |
| $424 | +3.72% | +39.29% | +42.89% | Year-end capital commitments for integrated digital surgical suites combine with peak deductible-driven procedure volumes. Free cash flow generation reaches new highs, encouraging institutional allocation toward defensive medtech compounders. | $388 | $494 | $910 | |
| $436 | +2.83% | +43.23% | +47.22% | Full-year reporting establishes a mature, cash-backed earnings foundation. Structural operating productivity offsets ongoing medical alloy and tariff inflation, enabling steady earnings-led appreciation while terminal valuation multiples remain disciplined. | $392 | $519 | $916 | |
| $449 | +3.10% | +47.50% | +51.92% | Outpatient surgical centers achieve mature utilization, with proprietary implants commanding leading share in decentralized facilities. Rapid inventory velocity and disciplined commercial overhead sustain robust quarterly operating earnings. | $404 | $535 | $937 | |
| $460 | +2.43% | +51.12% | +55.96% | Late-cycle macroeconomic headwinds and public healthcare budgetary reviews cap realized implant price increases. However, non-discretionary procedural necessity protects unit demand, keeping operating cash flow generation stable. | $412 | $556 | $947 | |
| $475 | +3.34% | +56.04% | +61.37% | Strong fourth-quarter surgical caseloads and replacement cycles for aging capital systems drive solid year-end shipments. Management authorizes expanded capital returns, cementing shareholder confidence across institutional allocators. | $424 | $573 | $970 | |
| $487 | +2.49% | +59.99% | +65.77% | Annual results confirm multi-year operating margin expansion toward cycle targets. Compounding free cash flow and a substantially fortified balance sheet position the business for sustainable long-term value creation. | $429 | $596 | $980 | |
| $502 | +2.98% | +64.91% | +71.23% | Next-generation surgical planning software updates defend robotic utilization across global hospital accounts. High-margin consumable attachment preserves operating profitability despite aggressive bidding from modular robotic competitors. | $437 | $613 | $1,000 | |
| $513 | +2.31% | +68.53% | +75.34% | The forecast horizon closes with robust operational execution and normalized cash flows validating franchise resilience. Steady organic volume growth and disciplined capital allocation deliver durable risk-adjusted equity compounding. | $446 | $632 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Stryker Stock Analysis & Scenarios Deep Dive
Stryker: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market consensus treats the business as a stumbling compounder burdened by compounding operational dysfunction, pointing to delayed vascular supply fixes, softer summer hip volumes, and high hospital borrowing hurdles. Media commentary and sell-side downgrades fixate on near-term multiple compression, assuming that elevated interest rates permanently cap institutional capital budgets and compress organic revenue growth.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates equity value by misdiagnosing transitory manufacturing bottlenecks as structural franchise decay, pricing shares at a rare cyclical discount. The analytical edge lies in recognizing that over three-quarters of revenue derives from non-cyclical procedural consumables and captive implants rather than discretionary capital equipment. While the market extrapolates delayed shipments into permanent share loss, installed robotic moats and outpatient procedural migration ensure that cash flows quickly reaccelerate once manufacturing throughput normalizes.
Repricing Catalyst
What could make the market recognize and close that gap? Consecutive quarterly earnings prints confirming complete manufacturing restoration across peripheral vascular lines and sustained organic growth above eight percent will decisively close the valuation gap. Institutional repricing will accelerate as capital equipment backorders convert into billed shipments and outpatient robotic placements demonstrate expanding market share throughout 2027, forcing sell-side analysts to lift forward earnings estimates.
Stryker: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Stabilization
Sentiment indicators agree that market positioning reflects oversold capitulation following operational disruptions. Disagreement centers on whether the stock has entered an early reversal or prolonged consolidation, dictated by whether fourth-quarter vascular supply milestones meet guidance.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing monetary regime of elevated policy rates and five-percent Treasury yields is a valuation headwind that tightens hospital capital budgets and raises financing hurdles for large equipment purchases. However, biological necessity renders joint replacement demand almost entirely price-inelastic, enabling strong operating cash flows to easily outpace broader macroeconomic stagflation.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical tension pits views assuming rapid mean-reversion in valuation multiples against those modeling a permanently lower multiple floor. The optimistic camp assumes that peripheral vascular bottlenecks will resolve cleanly by year-end, restoring high-single-digit organic growth and expanding operating margins past twenty-five percent. Conversely, skeptics argue that prolonged stockouts have permanently ceded procedural volume to competitors and that management guidance credibility has suffered. Resolving this disagreement requires observing third- and fourth-quarter vascular organic sales trends and verifying whether hospital capital equipment order backlogs convert cleanly into billed shipments.
Stryker: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Mako surgical ecosystem procedural lock-in | Competitive Positioning | +31% | +28% | An installed base exceeding three thousand robotic units performs over half of global robotic knee procedures, locking hospital orthopaedic suites into proprietary implants. High surgeon switching costs secure predictable high-margin consumable annuities, insulating cash flows from macro volatility and driving high-single-digit revenue expansion. |
| Demographic surge in non-discretionary arthroplasty | Sector And Industry | +22% | +24% | Accelerating global aging ensures an inelastic, non-cyclical wave of joint replacement, trauma, and extremity surgeries that patients cannot postpone indefinitely. This demographic expansion guarantees resilient procedural volume growth, underwriting predictable top-line revenue gains and providing durable cash flow protection across fluctuating economic cycles. |
| Ambulatory surgical center procedural migration | Innovation And Product | +20% | +20% | The rapid migration of orthopaedic procedures into outpatient surgical centers favors specialized, compact equipment. Commercial rollout of handheld robotics and turnkey surgical buildouts captures high-velocity outpatient accounts, lowering distribution friction, expanding operating margins, and driving superior capital turnover. |
| Peripheral vascular supply and synergy restoration | Operational Efficiency | +18% | +19% | Resolving manufacturing and cleanroom bottlenecks within acquired peripheral vascular facilities eliminates an estimated eighty basis points of organic drag. As production lines normalize, high-margin mechanical thrombectomy catheters ramp to scale, restoring operating leverage and accelerating consolidated earnings per share compounding. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Hospital capital expenditure financing squeeze | Macroeconomic And Macrofinancial | -14% | -11% | Elevated benchmark borrowing yields compress non-profit hospital operating margins and debt-financing capacity. Healthcare procurement committees are extending replacement cycles and scrutinizing major capital equipment purchases, dampening upfront robotic hardware shipments and lengthening sales cycles across institutional accounts. |
| Reimbursement containment and procurement caps | Regulatory | -11% | -10% | Public payers and commercial insurers continue tightening orthopaedic fee schedules, emphasizing bundled episode payments and site-neutral pricing. These regulatory caps restrict gross pricing flexibility on commodity implants, forcing ongoing manufacturing cost-reduction efforts to defend corporate operating margins. |
| Supply chain tariffs and input inflation | Operational Efficiency | -9.0% | -8.0% | Replacement Section 301 tariffs, trade frictions, and raw material inflation across medical-grade titanium and microelectronics elevate manufacturing costs. Multi-year fixed hospital procurement contracts prevent immediate wholesale price adjustments, creating persistent gross margin friction that trims operating profitability. |
| Post-acquisition debt service capital absorption | Capital Allocation | -8.0% | -7.0% | Substantial debt incurred to fund the nearly five-billion-dollar Inari Medical acquisition elevates annual interest commitments under higher refinancing rates. Slower balance sheet deleveraging absorbs discretionary operational cash flows, temporarily restricting share repurchases and moderating per-share earnings compounding. |
Stryker: What Could Break or Accelerate the Thesis
Event Risk Score: Very Low 18/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Prolonged vascular regulatory manufacturing sanctions | 24% | -26% | Persistent quality-control deficiencies or cleanroom yield failures at acquired peripheral vascular facilities could trigger an FDA warning letter or consent decree. Mandated facility halts and remediation expenses would forfeit high-margin procedural revenues, prompt material goodwill impairments, and cause lasting institutional valuation multiple de-rating. |
| Systemic clinical network cyberattack disruption | 19% | -28% | A sophisticated state-sponsored cyber offensive breaching operational networks or cloud-connected surgical telemetry could force mandatory device shutdowns across hospital operating rooms. Beyond immediate remediation and litigation expenses, clinical cancellations would impair customer trust and depress operating income across the device sector. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Accelerated outpatient robotics reimbursement parity | 32% | +24% | A decisive regulatory overhaul granting full procedural reimbursement parity and incentive bonuses for robotic-assisted joint replacements in ambulatory surgery centers would trigger rapid outpatient hardware adoption. Capturing dominant market share across expanding surgical centers would accelerate consumable implant pull-through and significantly increase earnings growth above current forecasts. |
| Autonomous soft-tissue robotic clearance | 26% | +28% | Securing accelerated FDA clearance for next-generation autonomous soft-tissue balancing algorithms embedded in robotic platforms would expand addressable surgical applications into spine and soft-tissue reconstruction. Faster operative throughput and reduced revision rates would spur an aggressive hospital replacement cycle, driving premium recurring software revenues. |
Company Financial AnalysisStryker: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Stryker financials here.
Earnings and financials
Stryker's financial performance highlights the remarkable resilience of its core medical business. Full-year 2025 revenue grew by 11.2% to $25.1 billion, and momentum continued with trailing revenue reaching $25.8 billion through mid-2026. While an early-2026 cyber incident and factory delays in peripheral vascular products caused temporary quarterly hiccups, underlying procedure demand rebounded quickly. Crucially, headline accounting figures obscure superior cash generation. Trailing free cash flow reached an impressive $4.70 billion, easily surpassing reported net income. Because surgical operations require constant replenishments of implants and single-use tools, revenue converts reliably into cash even during broader economic slowdowns.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 25.1B | USD 3.2B | USD 4.3B |
| 2024 | USD 22.6B | USD 3B | USD 3.5B |
| 2023 | USD 20.5B | USD 3.2B | USD 3.1B |
| 2022 | USD 18.4B | USD 2.4B | USD 2B |
| 2021 | USD 17.1B | USD 2B | USD 2.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 41.8x | TTM | Native | USD / USD |
| 2024 | 46.4x | TTM | Native | USD / USD |
| 2023 | 36.3x | TTM | Native | USD / USD |
| 2022 | 39.6x | Annual | Native | USD / USD |
| 2021 | 51.3x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Stryker demonstrates strong structural pricing power and operating efficiency across its operations. Gross margins widened to 64.0% in 2025, driven by premium pricing for specialized robotic implants and an advantageous mix of surgical instruments. While operating margins dipped temporarily to 19.5% in 2025 due to acquisition integration costs and supply chain friction, adjusted operating margins quickly rebounded above 22% on a trailing basis. As temporary factory bottlenecks clear and outpatient surgical centers expand, operating leverage will continue driving profits faster than sales.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 4.9B | 19.5% | 12.9% |
| 2024 | USD 5.1B | 22.4% | 13.2% |
| 2023 | USD 4.3B | 20.9% | 15.4% |
| 2022 | USD 3.7B | 20.2% | 12.8% |
| 2021 | USD 3.8B | 22.0% | 11.7% |
Balance sheet and leverage
The balance sheet reflects substantial financial strength built to withstand high interest rates. Stockholders' equity stood at $22.4 billion at the end of 2025, while debt-to-equity remained comfortable at 0.73 despite borrowing to finance the $4.9 billion Inari acquisition. With annual interest coverage well above eight times operating profit and a current ratio near 1.9, debt obligations are fully manageable. The company's massive annual free cash flow allows steady, orderly debt reduction, preserving complete borrowing flexibility for future technology investments without risking financial distress.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 16.4B | USD 4.1B | USD 12.3B net debt | USD 12.3B | 1.89x |
| 2024 | USD 1.4B | USD 4.4B | USD 9.9B net debt | USD -3B | 1.95x |
| 2023 | USD 13.5B | USD 3.1B | USD 10.5B net debt | USD 10.4B | 1.58x |
| 2022 | USD 13.5B | USD 1.9B | USD 11.7B net debt | USD 11.6B | 1.63x |
| 2021 | USD 12.5B | USD 3B | USD 9.5B net debt | USD 9.5B | 2.20x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management follows a disciplined, asset-light investment strategy that avoids sinking unnecessary money into heavy real estate or excess factories. Capital expenditures remain tightly controlled at roughly 3.0% of annual revenue, freeing up cash for higher-return opportunities. Instead of overbuilding physical facilities, the company reinvests heavily through its income statement, channeling $1.58 billion into research and development in 2025. This targeted spending funds proprietary robotic software and next-generation surgical tools, while operating cash flow self-funds strategic acquisitions like Inari Medical without overburdening core finances.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 761M | USD 1.6B |
| 2024 | USD 755M | USD 1.4B |
| 2023 | USD 575M | USD 1.3B |
| 2022 | USD 588M | USD 1.2B |
| 2021 | USD 525M | USD 1.1B |
Behind the synthesisStryker: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The independently supported consensus establishes that core reconstructive procedural demand is non-cyclical, sustained by demographic aging and an installed base of over three thousand robotic systems that command high-margin consumable implant pull-through. However, analytical divergence emerges regarding whether recent peripheral vascular manufacturing bottlenecks and summer orthopaedic softness represent brief operational friction or structural market share defection. Heaviest weights are allocated to reports that independently audit SEC filings, separate nonrecurring tariff refunds from structural margin gains, and account for management credibility headwinds following delayed remediation disclosures. Reports that mechanically assume an immediate re-rating to peak historical multiples are downweighted, as elevated sovereign yields and tight hospital capital expenditure budgets impose ongoing valuation friction.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 14.7%
Offering exceptional evidentiary rigor, this report cross-checks SEC filings, highlights working-capital distortions in trailing cash conversion, and identifies permanent procedural share loss during supply stockouts. Its grounded cash-flow valuation and disciplined multiple assumptions justify a top-tier weight.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 14.7%
This report delivers vital scrutiny of management credibility following September conference disclosures regarding slipped vascular remediation. It cleanly disaggregates nonrecurring tariff refunds from structural operating margin gains, providing indispensable balance against uncritical consensus optimism.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.8%
This analysis provides clear operational insight into Inari manufacturing yield friction and outpatient surgical migration. However, its expectation of swift multiple expansion to historical peak levels understates structural discount rates, warranting a measured baseline weighting.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.8%
This perspective models hospital procurement cycles and ambulatory surgical center bundling effectively. Nonetheless, its long-term multiple targets rely on uninterrupted double-digit EPS expansion that mildly discounts ongoing tariff overhead and capital equipment budgeting constraints.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.9%
Sound economic reasoning establishes that weight-loss medications do not diminish joint wear, while trailing free cash flow provides valuation support. However, its projected multiple re-expansion path slightly underweights hospital borrowing frictions in a restrictive interest rate environment.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.9%
This submission outlines owner earnings durability and capital allocation prudence, noting strong interest coverage. However, its assumption of rapid margin recovery toward historic peaks overlooks persistent medical component tariff friction and hospital procurement resistance.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.9%
Supported by verifiable secondary sources on outpatient platforms and commercial rollouts, this report provides a compelling industrial thesis. It receives a moderate weight due to somewhat optimistic multiple expansion assumptions.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.9%
The report accurately emphasizes recurring procedural consumables over lumpy hardware sales, but lacks fresh secondary source verification and models a rapid multiple recovery that brushes aside near-term vascular supply bottlenecks.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.9%
This analysis accurately identifies balance-sheet leverage following recent vascular transactions and highlights cash conversion quality. However, it lacks primary research citations and relies on an overly benign interest rate outlook.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.9%
While providing solid conceptual framing around demographic necessity, the report lacks independent primary source citations and relies on repeated qualitative assumptions regarding valuation multiple expansion back above thirty times earnings.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.9%
The thesis correctly captures outpatient migration dynamics, yet its aggressive valuation trajectory toward peak forward multiples relies heavily on speculative autonomous software monetization, necessitating a lower relative weighting.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.9%
The macro regime evaluation across economic cycles is coherent, but the analysis lacks fresh filing verification and models ambitious through-cycle margin expansion that underestimates hospital capital expenditure tightening.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.9%
The assessment correctly frames non-discretionary procedural necessity, but relies on overly philosophical prose, lacks external empirical documentation, and models excessive valuation re-expansion under sticky sovereign yields.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.9%
This submission outlines demographic volume drivers well, but duplicates the preceding report's framework and qualitative reasoning without providing fresh data verification, justifying a reduced standalone allocation.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Stryker forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web34 available sources from this batch (132 recorded). The first 15 are shown below; expand to read the rest.
- 8-K sec.gov
- syk-20260630 sec.gov
- www.sec.gov sec.gov
- Resilient Stryker stock holds after Q2 2026 earnings beat and fresh EPS guidance ad-hoc-news.de
- Stryker stock heads into the open after a 1.95% drop ad-hoc-news.de
- Stryker stock heads into the open after a 3.6% slide ad-hoc-news.de
- Stryker stock holds above $330 as investors weigh FY 2026 guidance ad-hoc-news.de
- Medical Technology Stocks: Innovation Endures as Valuations Reset bernstein.com
- [SYK Q2 2026 Earnings Call] Stryker Organic Sales Rise 9%, EPS Jumps 17.9%; Narrows 2026 Guidance on Strong Capital Backlog — BigGo Finance finance.biggo.com
- Stryker Corp (SYK) (Q2 2026) Earnings Call Highlights: Strong 9% Organic Growth and Raised ... finance.yahoo.com
- STRYKER CORP. R (SYK.MU) Q1 FY2026 earnings call transcript finance.yahoo.com
- Stryker Corporation (SYK) Stock Price, News, Quote & History - Yahoo Finance finance.yahoo.com
- Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS globenewswire.com
- Medical device stocks tumble after HCA flags weak surgical volumes By Investing.com investing.com
- Stryker at wells fargo healthcare conference: growth tested by supply By Investing.com investing.com
Show 19 more sources
- Stryker - Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment investors.stryker.com
- Stryker - Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment investors.stryker.com
- Stryker - Stryker to announce second quarter 2026 financial results investors.stryker.com
- Stryker Stock Declines as Manufacturing Issues Continue | MarketScreener marketscreener.com
- Stryker posts Q2 beats, narrows guidance after progress on cyberattack recovery massdevice.com
- Stryker stock falls on slower peripheral vascular, hip sales | MedTech Dive medtechdive.com
- Stryker Stock Falls 8.8% on Supply Chain Woes | Pomegra Briefs pomegra.io
- SYK 10K 12.31.2025 s22.q4cdn.com
- Stryker stock drops after CFO remarks (SYK:NYSE) | Seeking Alpha seekingalpha.com
- Stryker (NYSE:SYK) Stock Forecast & Analyst Predictions - Simply Wall St simplywall.st
- SYK - Aging Populations And Emerging Markets Will Transform Healthcare simplywall.st
- Stryker (SYK) FY 2026 Earnings Call Transcript & Audio stockanalysis.com
- Stryker (SYK) Stock Price & Overview stockanalysis.com
- Stryker (SYK) posts Q1 2026 growth, margins tighten but full-year outlook reaffirmed stocktitan.net
- Stryker posts Q2 2026 sales of $6.6 billion | SYK 8-K Filing stocktitan.net
- Customer Updates: Stryker Network Disruption stryker.com
- Mako Shoulder stryker.com
- Stryker expands Mako robotics portfolio with full market release of Mako RPS stryker.com
- Stryker Corp (SYK) AI Stock Analysis | Smart Price Targets & Insights - TipRanks.com tipranks.com
98 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.